Market Overview

Benzinga's Top #PreMarket Gainers

Related SNTA
InterMune's Roche Deal Sends Peer Group Up
Synta Announces Advancement Of Ganetespib Into Phase 3 Extension Of AML LI-1 Study For Patients With AML And High-Risk MDS
Related ISR
IsoRay Announces Positive Peer Review Of Cesium-131 In Treatment Of Metastatic Brain Cancer
Morning Market Movers

Synta Pharmaceuticals (NASDAQ: SNTA) surged 30.53% to $6.20 in the pre-market session on positive interim results from the ENCHANT-1 trial of ganetespib in metastatic breast cancer.

Sinovac Biotech (NASDAQ: SVA) shares gained 8.85% to $7.50 in the pre-market after the company reported unaudited Q4 results. Sinovac Biotech posted its quarterly net income of $5.8 million, or $0.10 per share, versus a year-ago net loss of $4.6 million, or $0.08 per share.

IsoRay (NYSE: ISR) surged 7.45% to $2.74 in pre-market trading as the company announced first pediatric Cesium-131 seeded mesh treatment for metastatic Wilms tumor.

Novavax (NASDAQ: NVAX) shares jumped 7% to $5.50 in pre-market trading after falling 4.10% on Wednesday.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers

 

Related Articles (ISR + NVAX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters